Patent
أعرض في EDS

Long-acting co-agonists of the glucagon and GLP-1 receptors

التفاصيل البيبلوغرافية
العنوان: Long-acting co-agonists of the glucagon and GLP-1 receptors
Patent Number: 10793,615
تاريخ النشر: October 06, 2020
Appl. No: 15/759911
Application Filed: October 21, 2016
مستخلص: Long-acting co-agonists of the glucagon and GLP-1 receptors are described.
Inventors: Merck Sharp & Dohme Corp. (Rahway, NJ, US); Palani, Anandan (Bridgewater, NJ, US); Nargund, Ravi (East Brunswick, NJ, US); Carrington, Paul E. (South San Francisco, CA, US); Sawyer, Tomi (Southborough, MA, US); Deng, Qiaolin (Edison, NJ, US); Pessi, Antonello (D'Europa, IT); Bianchi, Elisabetta (Pomezia, IT); Orvieto, Federica (Pomezia, IT)
Assignees: Merck Sharp & Dohme Corp. (Rahway, NJ, US)
Claim: 1. A peptide comprising the formula [table included] wherein X 2 is aminoisobutyric acid (aib), D-Ser or alpha-Methyl-L-Serine (alpha-MS); X 9 is Asp or alpha-Methyl-L-Aspartic acid (alpha-MD); X 10 is Lys conjugated to a fatty diacid, p-aminomethyl-L-phenylalanine (pAF) conjugated to a fatty diacid or Tyr-; X 12 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Lys, or (1S,2S)-Fmoc-2-aminocyclopentane carboxylic acid (βc); X 14 is Leu or alpha-L-Leucine (alpha-ML); X 16 is aib, Ala, or Glu; X 20 is Lys is conjugated to a fatty diacid, pAF conjugated to a fatty diacid or Gln; X 21 is Lys conjugated to a fatty diacid, pAF conjugated to a fatty diacid, Asp, or alpha-MD; X 22 is Phe or alpha-Methyl-L-phenylalanine (alpha-MF); X 24 is Gln (1S,2S)-Fmoc-2-aminocyclopentane carboxylic acid (βc), Lys conjugated to a fatty diacid or pAF conjugated to a fatty diacid; X 27 is L-Met sulphone or Leucine; X 28 is Asp, alpha-MD, alpha-Methyl-L-Tryptophan (alpha-MW), Lys, Ala, Lys conjugated to a fatty diacid, or pAF conjugated to a fatty diacid; and X 30 is Lys linked at the C-terminus to gamma-Glu when X 27 is Leu and X 28 is Ala, or absent; with the proviso that for each peptide, only one of X 10 , x 12 , x 20 , X 21 , X 24 , or X 28 is conjugated to a fatty diacid.
Claim: 2. The peptide of claim 1 , wherein the fatty diacid comprises a C14, C15, C16, C17, C18, C19, or C20 fatty diacid.
Claim: 3. The peptide of claim 1 , wherein the peptide comprises the fatty diacid conjugated to the Lys or pAF via a gamma-Glu, gamma-Glu linker.
Claim: 4. The peptide of claim 1 , wherein the peptide comprises the fatty diacid conjugated to Lys or pAF via a PEG 2 PEG 2 -gamma-Glu linker wherein PEG 2 is 8-amino-3,6-dioxaoctanoic acid.
Claim: 5. The peptide of claim 1 , wherein the peptide comprises at X 10 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
Claim: 6. The peptide of claim 1 , wherein the peptide comprises at x 12 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
Claim: 7. The peptide of claim 1 , wherein the peptide comprises at x 20 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
Claim: 8. The peptide of claim 1 , wherein the peptide comprises at x 21 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
Claim: 9. The peptide of claim 1 , wherein the peptide comprises at x 24 the pAF conjugated to a fatty diacid or a Lys conjugated to a fatty diacid.
Claim: 10. A composition comprising one or more peptides of claim 1 , or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Claim: 11. A composition comprising one or more peptides of claim 1 , or pharmaceutically acceptable salt thereof, an insulin or insulin analog, and a pharmaceutically acceptable carrier.
Claim: 12. The composition of claim 11 , wherein the insulin analog comprises insulin detemir, insulin glargine, insulin glulisine, insulin degludec, or insulin lispro.
Claim: 13. A method for treating a patient for a metabolic disease or disorder comprising administering to a patient in need thereof an effective amount of one or more of the peptides of claim 1 to treat the metabolic disease or disorder in the patient wherein, the metabolic disease or disorder comprises diabetes, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
Claim: 14. The method of claim 13 , wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.
Claim: 15. A method for treating a metabolic disease or disorder in a patient comprising administering to the patient in need thereof an effective amount of one or more of the peptides of claim 1 and administering to the patient in need thereof an effective amount of a composition comprising an insulin or insulin analog to treat the metabolic disease or disorder in the patient, wherein the metabolic disease or disorder comprises diabetes, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or obesity.
Claim: 16. The method of claim 15 , wherein the insulin analog comprises insulin detemir, insulin glargine, insulin levemir, insulin glulisine, insulin degludec, or insulin lispro.
Claim: 17. The method of claim 15 , wherein the diabetes comprises Type I diabetes, Type II diabetes, or gestational diabetes.
Patent References Cited: 6852690 February 2005 Nauck et al.
2012/0165503 June 2012 Carrington et al.
2013/0090286 April 2013 Bianchi et al.
2013200675 March 2015
WO2003022304 March 2003
WO2004062685 July 2004
WO2006134340 December 2006
WO2008101017 August 2008
WO2009155258 December 2009
2010071807 June 2010
WO2010096052 August 2010
WO2011075393 June 2011
WO2012177443 December 2012
WO2012177444 December 2012
2014158900 October 2014
2016065090 April 2016
Other References: Lantus prescribing information, accessed Feb. 11, 2020 at URL: accessdata.fda.gov/drugsatfda_docs/label/2009/021081s034lbl.pdf; Jun. 2009, pp. 1-24 (Year: 2009). cited by examiner
Cornier et al., “The Metabolic Syndrome”, Endo. Rev. 29:777-822 (2008) (Year: 2008). cited by examiner
Metabolic disease, Encyclopedia Britannica, accessed Feb. 12, 2020 at URL: britannica.com/science/metabolic-disease; pp. 1-17 (2019) (Year: 2019). cited by examiner
Baggio et al., Oxyntomodulin and Glucagon-Like Peptide-1 Differentially, Gastroenterol., 2004, pp. 546-558, 127. cited by applicant
Choudhri et al., Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging, Biochem. Biophys. Res. Commun., 2006, pp. 298-306, 350. cited by applicant
Cohen et al., Oxyntomodulin Suppresses Appetite and Reduces Food intake in Humans, J. Clin. Endocrinol. Metab., 2003, pp. 4696-4701, 88. cited by applicant
Dakin et al., Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet, Am. J. Physiol. Endocrinol. Metab., 2008, pp. E142-E147, 294. cited by applicant
Dakin et al., Oxyntomodulin Inhibits Food Intake in the Rat, Endocrinology, 2001, pp. 4244-4250, 142. cited by applicant
Dakin et al., Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats, Endocrinology, 2004, pp. 2687-2695, 145. cited by applicant
Dakin et al., Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats, Am. J. Physiol. Endocrinol. Metab., 2002, pp. E1173-E1177, 283. cited by applicant
Day, Jonathan W., A New Glucagon and GLP 1 co agonist eliminates obesity in rodents, Nature Chemical Biology, 2009, No. 10 pp. 749-757, 5. cited by applicant
Drucker et al., Biologic actions and therapeutic potential of the proglucagon-derived peptides, J. Nat. Clin. Pract. Endocrinol. Metab., 2005, pp. 22-31, 1. cited by applicant
Habegger et al., The metabolic actions of glucagon revisited, Nat. Rev. Endocrinol., 2010, pp. 689-697, 6. cited by applicant
Holst, Gut hormones as pharmaceuticals From enteroglucagon to GLP-1 and GLP-2, Regul. Pept., 2000, pp. 45-51, 93. cited by applicant
Jarrouse et al., A Pure Enteroglucagon, Oxyntomodulin (Glucagon 37), Stimulates Insulin Release in Perfused Rat Pancreas, Endocrinol., 1984, pp. 102-105, 115. cited by applicant
Jiang et al., Glucagon and regulation of glucose metabolism, Am. J. Physiol. Endocrinol. Metab., 2003, pp. E671-E678, 284. cited by applicant
Jorgensen et al., Oxyntomodulin Differentially Affects Glucagon-Like Peptide-1 Receptor Beta-Arrestin Recruitment and Signaling through G alpha s, J. Pharma. Exp. Therapeut., 2007, pp. 148-154, 322. cited by applicant
Lykkegaard et al., Regulatory Role of Glucose and Melanocortin 4 Receptor in AMP-Activated Protein Kinase Activity in the Hypothalamus: Association with Feeding Behavior, ADA Scientific Sessions, Abstract No. 1506 P, 2003, Abstract No. 1506P, Abstract No. 1506P. cited by applicant
Pocai et al., Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice, Diabetes, 2009, pp. 2258-2266, 58. cited by applicant
Salter, Metabolic Effects of Glucagon in the Wistar Rat, Am. J. Clin. Nutr., 1960, pp. 535-539, 8. cited by applicant
Schjoldager et al., Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man, Eur. J. Clin. Invest., 1988, pp. 499-503, 18. cited by applicant
Sowden et al., Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor, Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, pp. R962-R970, 292. cited by applicant
Wynne et al., Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects, Diabetes, 2005, pp. 2390-2395, 54. cited by applicant
Zhu et al., The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides, J. Biol. Chem., 2002, pp. 22418-22423, 278. cited by applicant
Lau, Jesper et al., Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide, Journal of Medicinal Chemistry, 2015, 7370-7380, 58(18). cited by applicant
Assistant Examiner: Hellman, Kristina M
Primary Examiner: Ha, Julie
Attorney, Agent or Firm: Brown, Baerbel R.
Fitch, Catherine D.
رقم الانضمام: edspgr.10793615
قاعدة البيانات: USPTO Patent Grants
الوصف
الوصف غير متاح.